Prostate Cancer and Personal Journeys

Nearly seven years post-retirement, David Bulteel should be relishing the achievements from his 40-year career in the city. On the surface, he seems to have it all: a comfortable pension, beloved grandchildren, and a spacious home in Buckinghamshire. He’s an upbeat individual, driven by a determination that partly stems from the trauma of losing his right arm in a motorcycle accident at the age of 21. His colleagues affectionately nicknamed him “Tigger” due to his boundless energy and enthusiasm.

“I’ve always believed that there’s no problem that can’t be solved,” Bulteel, now 70, shares while bundled up in two jumpers during one of the coldest days of winter. “But the reality is I’ve been grappling with this shadow for 13 years, and it’s deeply affected not just me but my entire family.”

During his career, Bulteel’s employer offered biannual health checks, which included a simple blood test for prostate-specific antigen (PSA) levels. Normally, low PSA levels are nothing to worry about, but higher levels can signal potential prostate cancer.

In 2012, when Bulteel was 52, his PSA test came back elevated. He wasn’t familiar with the implications, but a conversation with an oncologist revealed a family history of prostate issues, driving home the point that his risk had substantially increased.

A biopsy confirmed he had prostate cancer, which can be hereditary. Unfortunately, unlike his brother’s case, Bulteel’s cancer had begun to spread, igniting an exhausting cycle of surgeries, radiation, hormone treatments, MRI scans, and frequent PSA tests. This process has led to other health complications, including heart problems, bladder issues, and severe impacts on his mental health.

“It’s incredibly tough,” Bulteel admits, anxiously awaiting the results of another scan. “This could either mean I’m stepping towards an ‘all clear’ or more distressing news. But I’m aware that many men face similar battles.”

Prostate cancer has become the most frequently diagnosed cancer in the UK, as noted by Prostate Cancer UK. The latest NHS data indicates there were nearly 65,000 cases in 2022, surpassing breast cancer diagnoses by around 3,000. Roughly one in eight men will encounter this cancer at some point, and about 12,200 men die from it each year.

Phil Pennington, a police officer in Merseyside, recalls receiving an email from his federation about the opportunity for free private screenings. “Funny enough, I went for the test after a rough couple of days just to take a break from work,” says Pennington, who began his policing career at 28 after working in construction.

His PSA was high, and subsequent scans revealed aggressive prostate cancer. “Doctors told me that if it had gone undetected for another year, it would have been too late for treatment.” He underwent surgery in 2023, followed by radiotherapy and hormone therapy to curb testosterone production, essential for prostate cancer growth.

His PSA levels have dropped significantly, and there’s a sense of optimism from his doctors. Yet, the emotional toll remains. “It was a wake-up call,” he reflects, remembering how he worried about not being there for his children during Christmas when they were six and eleven.

The uptick in diagnoses is, in part, thanks to awareness campaigns and public figures sharing their experiences. Individuals like the late BBC presenter Bill Turnbull have brought visibility to the issue, prompting more men to recognize symptoms like changes in urination, erectile dysfunction, and unexplained weight loss.

However, disparities in testing arise when economic inequality factors in, with Prostate Cancer UK finding those in deprived areas 29% more likely to have advanced cancer at diagnosis than their wealthier counterparts.

This has sparked discussions about the need for better access to screenings, especially after the UK National Screening Committee recently decided against a broad screening program. Prostate Cancer UK and Prostate Cancer Research advocate for wider screening measures.

The committee recommended screening every two years for men aged 45-61 with certain genetic factors. While men can request PSA tests via their GPs, the panel found that the risks of broader screening might outweigh the benefits, even for identified at-risk groups.

The PSA test itself is not foolproof; it can either miss cancers or lead to false positives, causing unnecessary treatments that might inflict serious side effects without extending lives. Some estimates suggest that for every 1,000 men screened, around 20 might be overdiagnosed, with 12 undergoing overtreatment.

Despite these statistics, Prostate Cancer UK supports expanded screening, particularly for high-risk groups. They argue that even if two lives are saved per 1,000 screenings, the potential to benefit at-risk individuals is significant. Meanwhile, Bulteel views his initial PSA test as critical. “As my urologist noted, it’s vital to watch for changes in PSA levels, not just the number itself.”

Other men have also shared their stories. Martin Walsh, a retired purchasing manager, regretted not getting tested earlier, especially with his family history. Eventually, he faced cancer after experiencing symptoms and is currently undergoing a new, more efficient radiotherapy treatment.

Junior Hemans, a former management consultant, recognized the necessity of health checkups when he turned 50. Understanding the elevated risk for Black men made him proactive about checking, leading to an early cancer diagnosis. He now advocates for better awareness and testing protocols among at-risk demographics.

Bulteel’s hormone treatment introduced unforeseen challenges. The reduction in testosterone affected his mood and physicality, prompting him and his wife to seek counseling regarding the changes in their relationship. “Staying alive is a priority, but the quality of life can’t be ignored,” he reflects.

His family urged him to address his mental health struggles. During a particularly tough time when treatment progress appeared stagnant, he had to share with his children the harsh possibility of a limited time left. “That was devastating,” he admits.

Currently, Bulteel faces the prospect of adjusting his treatment as the cancer shows signs of growth again. “It’s not dire yet, but I may need to add another medication to maintain effectiveness,” he says cautiously.

Feeling fortunate for having access to private screenings, he also harbors a lingering concern of potential earlier diagnosis. “I don’t want to paint a bleak picture; I’m managing, but had I caught this sooner, I might be living a different reality like my brother, who is now cancer-free.”